Tag: medical

Enthea, the healthcare provider that specializes in psychedelic therapy, announced on Tuesday that it will “launch its services into 40 markets across the U.S. next year as well as grow Enthea’s customer base and provider network to further its mission of providing affordability and access to safe and effective psychedelic-assisted therapies for all who can benefit.”

The ambitious launch is the byproduct of a “successful $2M seed round raise, led by Tabula Rasa Ventures, the first psychedelic accelerator for early-stage startups,” the company said in the announcement.

Enthea says that the driving force behind the new endeavor is to improve access to potentially breakthrough psychedelic treatment amid an ever-spiraling mental health crisis in the United States.

The company asserts that it is “helping in this mental health crisis by bringing employer funding for these new treatments,” saying that “traditional health insurers are years away from adding this coverage, the cost

The U.S. Senate on Wednesday approved landmark legislation to expand medical marijuana research, marking the first time both chambers of Congress have passed a standalone cannabis bill. The measure, titled the Medical Marijuana and Cannabidiol Research Expansion Act, received the approval of the House of Representatives during the summer and now heads to the desk of President Joseph Biden for his consideration.

Democratic Representative Earl Blumenauer of Oregon, the co-sponsor of the legislation in the House along with Maryland Republican Representative Andy Hariss, noted the significance of the legislation after the Senate vote on Wednesday.

“After working on the issue of cannabis reform for decades, finally the dam is starting to break. The passage of my Medical Marijuana and Cannabidiol Research Expansion Act in the House and Senate represents a historic breakthrough in addressing the federal government’s failed and misguided prohibition of cannabis,” Blumenauer, the founder and co-chair of the

A study published Wednesday in Neuropsychology attempted to determine if CBD reduces the adverse effects of THC, such as paranoia and memory loss, but found little evidence to support this theory. Study participants were observed and both pleasurable effects as well as adverse effects like paranoia and memory recall were recorded.

The study, called “Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios” aimed to determine if increasing the amount of CBD can reduce the “harmful effects” of cannabis—notably from THC.

Cannabis products are typically marketed with CBD:THC ratios, with CBD frequently being touted to augment THC’s effects, leading researchers to explore the relationship between the plant’s two most popular compounds. But they found that CBD doesn’t necessarily show evidence of reducing adverse side effects.

Forty-six individuals, ages 21-50, who consume cannabis infrequently, were observed and given an initial baseline visit—followed by

Many will attest, alongside myriad additional studies, to the sedative, relaxing qualities of cannabis as a sleep aid. Now, a new study published in the Journal of Sleep Research adds additional insight surrounding the benefits of cannabis for treating insomnia, finding that the short-term use of plant-derived cannabis extracts is well-tolerated and effective for patients diagnosed with insomnia.

Insomnia involves difficulty falling or staying asleep and is relatively common, experienced by up to 30% of the general population. In their introduction, the authors point to the potential for cannabis to help alleviate sleep dysfunction along with the impact of individual cannabinoids on sleep. Specifically, they reference the sedative effect of THC and the potential of CBD as a sedative in higher doses.

The trial looked to assess the tolerability and effectiveness of medicinal cannabis oil on sleep in adults with insomnia. The study was conducted between May 2020 and May